JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes. Here, we showed that combined expression...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenney, Anna Sophia, Lau, Allison N., Somasundara, Amritha Varshini Hanasoge, Spitzer, Barbara, Intlekofer, Andrew M., Ahn, Jihae, Shank, Kaitlyn, Rapaport, Franck T., Patel, Minal A., Papalexi, Efthymia, Shih, Alan H., Chiu, April, Freinkman, Elizaveta, Akbay, Esra A., Steadman, Mya, Nagaraja, Raj, Yen, Katharine, Teruya-Feldstein, Julie, Wong, Kwok-Kin, Rampal, Raajit, Heiden, Matthew G. Vander, Thompson, Craig B., Levine, Ross L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785272/
https://www.ncbi.nlm.nih.gov/pubmed/29355841
http://dx.doi.org/10.1172/JCI94516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785272/
https://www.ncbi.nlm.nih.gov/pubmed/29355841
http://dx.doi.org/10.1172/JCI94516

Ejemplares similares